{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:59:44Z","timestamp":1758819584643},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1985,3,1]],"date-time":"1985-03-01T00:00:00Z","timestamp":478483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[1985,3]]},"DOI":"10.1007\/bf00314036","type":"journal-article","created":{"date-parts":[[2004,10,10]],"date-time":"2004-10-10T17:42:06Z","timestamp":1097430126000},"page":"24-28","source":"Crossref","is-referenced-by-count":4,"title":["Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism"],"prefix":"10.1007","volume":"232","author":[{"given":"E.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-A.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Japp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"303","volume-title":"Pathophysiologie, Klinik und Therapie des Parkinsonismus","author":"H Baas","year":"1983","unstructured":"Baas H, Schneider E, Fischer PA (1983) Cu 32-085 versus Bromocriptin in der Kombinationstherapie des Parkinsonsyndrom. In: G\ufffdnshirt H (ed) Pathophysiologie, Klinik und Therapie des Parkinsonismus. Editiones Roches, Basel Grenzach Wyhlen, pp 303?308"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00313593","volume":"230","author":"H Biesemeyer","year":"1983","unstructured":"Biesemeyer H, Ludin HP, Ringwald E (1983) Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease. J Neurol 230:19?23","journal-title":"J Neurol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/0024-3205(81)90494-X","volume":"29","author":"A Enz","year":"1981","unstructured":"Enz A (1981) Biphasic influence of a 8-alpha-amino-ergoline, CU 32-085, on striatal dopamine synthesis and turnover in vivo in the rat. Life Sci 29:2227?2234","journal-title":"Life Sci"},{"key":"CR4","unstructured":"Enz A, Frick W, Closse A, Nordmann R (1982) Dopaminergic properties of CU 32-085 and its 1,20-N,N-bidemethylated metabolite. In: Abstracts of the 13th CINP Congress, Jerusalem, 20?25 June, 1982, vol 1, A?N: 199. Collegium Internationale Neuro-Psychopharmacologicum"},{"key":"CR5","doi-asserted-by":"crossref","unstructured":"Enz A, Donatsch P, Nordmann R (1984) Dopaminergic properties of mesulergine (CU 32-085) and its metabolites. J Neurol Transm (in press)","DOI":"10.1007\/BF01249095"},{"key":"CR6","volume-title":"Dopaminergic agents in the mangement of neurological disorders","author":"A Enz","year":"1984","unstructured":"Enz A, Dontsch P, Briner U, Jaton AL, Markstein R, Palacios JM (1984) Dopaminergic profile of mesulergine. In: Agid Y, Jenner P, Lataste X (eds) Dopaminergic agents in the mangement of neurological disorders. Academic Press. London Oxford (in press)"},{"key":"CR7","volume-title":"Pharmacology of CU 32-085","author":"E Fl\ufffdckiger","year":"1980","unstructured":"Fl\ufffdckiger E (1980) Pharmacology of CU 32-085. Sandoz Ltd, Basle"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/BF01953267","volume":"35","author":"E Fl\ufffdckiger","year":"1979","unstructured":"Fl\ufffdckiger E, Briner U, B\ufffdrki HR, Marbach P, Wagner HR, Doepfner W (1979) Two novel prolactin release-inhibiting 8-alpha-amino-ergolines. Experienta 35:1677?1678","journal-title":"Experienta"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00313773","volume":"227","author":"K Jellinger","year":"1982","unstructured":"Jellinger K (1982) Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085. J Neurol 227:75?88","journal-title":"J Neurol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00342499","volume":"216","author":"K Kendel","year":"1972","unstructured":"Kendel K, Beck U, Wita C, Hohneck E, Zimmerman H (1972) Der Einflu\ufffd von l-Dopa auf den Nachtschlaf bei Patienten mit Parkinsonsyndrom. Arch Psychiatr Nervenkr 216:82?100","journal-title":"Arch Psychiatr Nervenkr"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1212\/WNL.30.5.518","volume":"30","author":"AN Lieberman","year":"1980","unstructured":"Lieberman AN, Kupersmith M, Neophytides A, Casson I, Durso R, Foo SH, Khayahi M, Bear G, Goldstein M (1980) Long-term efficacy of bromocriptine in Parkinson's disease. Neurology (NY) 30:518?523","journal-title":"Neurology"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S0317167100046473","volume":"11","author":"AN Lieberman","year":"1984","unstructured":"Lieberman AN, Copinathan G, Hassouri H, Neophytides A, Goldstein M (1984) Should dopamine agonists be given early or late? A review of nine years experience with bromocriptine. Can J Neurol Sci 11:233?237","journal-title":"Can J Neurol Sci"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0014-2999(83)90272-8","volume":"95","author":"R Markstein","year":"1983","unstructured":"Markstein R (1983) Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1 and D2 receptors. Eur J Pharmacol 95:101?107","journal-title":"Eur J Pharmacol"},{"key":"CR14","first-page":"401","volume":"138","author":"A Rascol","year":"1982","unstructured":"Rascol A, Montastruc JL, Guirand-Chaumeil B, Clanet M (1982) La bromocriptine comme premier traitment de la maladie de Parkinson: r\ufffdsultat \ufffd long terme. Rev Neurol 138:401?408","journal-title":"Rev Neurol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S0317167100046461","volume":"11","author":"A Rascol","year":"1984","unstructured":"Rascol A, Montastruc JL, Rascol O (1984) Should dopamine agonists be given early or late in the treatment of Parkinson's disease. Can J Neurol Sci 11:229?232","journal-title":"Can J Neurol Sci"},{"key":"CR16","first-page":"431","volume-title":"Lisuride and other dopamine agonists","author":"UK Rinne","year":"1983","unstructured":"Rinne UK (1983) New ergot derivates in the treatment of Parkinson's disease. In: Calne DB, McDonald RJ, Jorowski R, Wutke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 431?442"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF00313415","volume":"228","author":"E Schneider","year":"1982","unstructured":"Schneider E, Fischer PA (1982) Long-term experience with bromocriptine in advanced parkinsonism. Results after one year's treatment. J Neurol 228:249?258","journal-title":"J Neurol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00594087","volume":"207","author":"E Schneider","year":"1974","unstructured":"Schneider E, Maxion H, Ziegler B, Jacobi P (1974) Das Schlafverhalten von Parkinsonkranken und seine Beeinflussung durch l-Dopa. J Neurol 207:95?108","journal-title":"J Neurol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1212\/WNL.33.4.468","volume":"33","author":"E Schneider","year":"1983","unstructured":"Schneider E, Hubener K, Fischer PA (1983) Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085. Neurology (Cleveland) 33:468?472","journal-title":"Neurology"},{"key":"CR20","first-page":"527","volume":"40","author":"E Schneider","year":"1984","unstructured":"Schneider E, Hubener K, Fischer PA (1984) Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients. In: Hassler GG, Christ JF (eds) Parkinson-specific motor and mental disorders. Adv Neurol 40:527?529","journal-title":"Adv Neurol"},{"key":"CR21","first-page":"163","volume-title":"Vegetativst\ufffdrungen bei Parkinson-Kranken","author":"E Schneider","year":"1984","unstructured":"Schneider E, Ziegler B, Jacobi P (1984) Schlafst\ufffdrungen beim Parkinson-Syndrom. In: Fischer P-A (ed) Vegetativst\ufffdrungen bei Parkinson-Kranken. Editiones Roche, Basel, pp 163?183"},{"key":"CR22","volume-title":"Depaminergic agents in the management of neurological disorders","author":"E Schneider","year":"1984","unstructured":"Schneider E, Baas H, Fischer PA (1984) Long-term comparison between bromocriptine and mesulergine (CU 32-085) in advanced parkinsonism. Preliminary report. In: Agid Y, Jenner P, Lataste X (eds) Depaminergic agents in the management of neurological disorders. Academic Press, London Oxford (in press)"},{"key":"CR23","first-page":"161","volume-title":"Actualit\ufffds de chemique th\ufffdrapeutique, 9\ufffdme Serie","author":"JM Vigouret","year":"1982","unstructured":"Vigouret JM, Fl\ufffdckiger E, B\ufffdrki HR, Enz A, Jaton AL (1982) Apercu sur quelques propri\ufffdt\ufffds pharmacologiques de nouveaux d\ufffdriv\ufffds de l'ergot de seigle. Actualit\ufffds de chemique th\ufffdrapeutique, 9\ufffdme Serie. Lavoisier, Paris, pp 161?165"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00314036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00314036\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00314036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T19:08:17Z","timestamp":1554318497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00314036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,3]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1985,3]]}},"alternative-id":["BF00314036"],"URL":"https:\/\/doi.org\/10.1007\/bf00314036","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,3]]}}}